logo

For the Inventor, By the Inventor

Lyon, France

Poxel Sa

Calculating rank
USPTO Granted Patents = 12


Forward Citations = 2

Loading Chart...
Loading Chart...

19 inventors (with patents filed for the assignee):

goldMedal Vincent Jacques (6 out of 30 patents)

silverMedal Sheila DeWitt (5 out of 21 patents)

bronzeMedal Sébastien Bolze (4 out of 11 patents)

4.  Leonardus Van Der Ploeg (4 out of 4 patents)

5.  Anthony W Czarnik (3 out of 32 patents)

6.  Laure Françoise Valérie Navarre (2 out of 2 patents)

7.  Bill Symonds (2 out of 2 patents)

8.  Steve Piscitelli (2 out of 2 patents)

9.  Karen Segal (2 out of 2 patents)

10.  Ruby Holder (2 out of 2 patents)

11.  Sophie Bozec (2 out of 2 patents)

12.  Pascale Fouqueray (2 out of 2 patents)

13.  Christophe Arbet-Engels (2 out of 2 patents)

14.  Julie Dubourg (2 out of 2 patents)

15.  Paul Strumph (2 out of 4 patents)


12 patents:

1. 12036226 - Methods of treating subjects having diabetes with chronic kidney disease (2024-07-16),
2. 11918569 - 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same (2024-03-05),
3. 11918567 - Deuterium-enriched pioglitazone (2024-03-05),
4. 11767317 - Methods of synthesizing enantiopure deuterium-enriched pioglitazone (2023-09-26),
5. 11617754 - Methods of treating heart failure with preserved ejection fraction (2023-04-04),
6. 11319313 - Crystalline forms of deuterium-enriched pioglitazone (2022-05-03),
7. 11266652 - Methods of treating subjects having diabetes with chronic kidney disease (2022-03-08),
8. 11141411 - Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone (2021-10-12),
9. 11123336 - 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same (2021-09-21),
10. 10940143 - Deuterium-enriched pioglitazone (2021-03-09),
11. 10576071 - Deuterium-enriched pioglitazone (2020-03-03),
12. 10265305 - 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same (2019-04-23),
Company Overview
Poxel SA is a biopharmaceutical company based in Lyon, France, specializing in the development of innovative treatments for metabolic diseases, particularly diabetes and obesity. The company focuses on advancing its proprietary drug candidates through rigorous research and clinical development, leveraging its expertise in pharmacology and metabolic science. Poxel is committed to addressing unmet medical needs and improving patient outcomes by harnessing cutting-edge technology and scientific knowledge in the field of metabolic disorders.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

12 Patents

#33 in Lyon

#1,487 in France

#48,235 in the World

Lyon, FR
Lyon, France

Poxel Sa

Forward Citations = 2

19 inventors:

goldMedal Vincent Jacques (6 out of 30 patents)

silverMedal Sheila DeWitt (5 out of 21 patents)

bronzeMedal Sébastien Bolze (4 out of 11 patents)

4.  Leonardus Van Der Ploeg (4 out of 4 patents)

5.  Anthony W Czarnik (3 out of 32 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Poxel Sa. Retrieved from https://idiyas.com/company/poxel-sa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…